Analysed BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) News Sources
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
15-04-2026
yahoo.com
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
09-04-2026
yahoo.com
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
25-02-2026
yahoo.com
Basilea Pharmaceutica Ltd (BPMUF) Full Year 2025 Earnings Call Highlights: Strong Revenue ...
17-02-2026
yahoo.com
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
17-02-2026
yahoo.com
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight
09-02-2026
yahoo.com
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
09-02-2026
yahoo.com
What is the current price of BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS)?
The current price of BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) is $0.
BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) since the previous trading day is $None.
BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS)?
The most recent average sentiment score for BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) is 76 out of 100.
What is the most recent average sentiment for BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS)?
The most recent sentiment for BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS) is .
SEC-8K** Filing Available For BASILEA PHARMACEUTICA-REG (BPMUF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.